Melodia

Quick links to important sections

Melodia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melodia

What is Melodia? Overview

Property Description
Active ingredient Ethinyl Estradiol and Gestodene
Form Film-coated tablet (Oral)
Pharmacological class Combined Oral Contraceptive (COC)
General purpose Contraception (prevention of pregnancy)
Origin Synthetic, fixed-dose preparation

Defining Melodia: Pharmacological Identity and Purpose

Melodia is a synthetic, fixed-dose pharmaceutical preparation classified as a Combined Oral Contraceptive (COC). Its sole general purpose, clinically recognized across numerous health organizations, is to provide highly effective contraception, achieved by influencing the female reproductive cycle through systemic hormonal modulation.

This medicine belongs to the pharmacological class of Sex Hormones and Modulators of the Genital System (ATC G03A). As a COC, it functions as a prophylactic agent that utilizes a specific combination of two synthetic hormones, establishing a continuous state of protection for the prevention of pregnancy. The classification confirms the drug's established function as a primary method of birth control.

Composition and Drug Form: Estrogen and Gestodene Components

The two active ingredients [INN] in Melodia are Ethinyl Estradiol and Gestodene. The medication is a combination product formulated as an oral contraceptive tablet, specifically a film-coated tablet, and is administered via the oral route. The formulation stands out because it utilizes Gestodene, which is categorized as a third-generation progestin component. Third-generation progestins, such as Gestodene, are supported by pharmaceutical research for their specific receptor affinity. Melodia is a monophasic formulation, ensuring the dosage of both the estrogen and progestin remains constant across every active tablet within the cycle, providing a consistent hormonal profile.

How Does Melodia Relate to Other Hormonal Contraceptives?

The physiological action of the Ethinyl Estradiol and Gestodene combination ensures a reliable, continuous state of prophylaxis. The primary action is the suppression of ovulation, or ovarian function inhibition, which halts the monthly release of an egg.

This COC formulation achieves its effect through a triple mechanism: halting ovulation, causing a modification of cervical mucus to impede sperm, and inducing endometrial alteration in the uterine lining. These combined mechanisms of effect fulfill the product's fundamental purpose of providing contraception.

Regulatory References

  1. French National Drug Register (Melodia)

What side effects are possible with Melodia?

Safety Profile and Adverse Reactions

The safety profile of Melodia (Ethinyl Estradiol and Gestodene) is established through regulatory classification, which defines both common and serious potential adverse reactions. The incidence of effects is categorized based on official frequency standards.

Classification Examples of Adverse Reactions (Per Regulatory Sources)
Very Common Headache, Spotting or Breakthrough bleeding.
Common Nausea, Vomiting, Abdominal pain, Mood changes (including depression), Breast pain/tenderness, Weight gain.
Uncommon Migraine, Fluid retention, Change in libido, Hypertension, Rash.

The most frequent effects are generally non-serious and involve the Nervous System (headache) and the Reproductive System (bleeding irregularities). Adverse reactions are also documented across other System-Organ Classes, including Gastrointestinal, Psychiatric, and Skin and Subcutaneous Tissue Disorders.


Serious Adverse Reactions and Safety Constraints

The most serious, albeit rare, adverse reactions documented in regulatory sources are Thromboembolic Events and Hepatic Neoplasms.

  • Thromboembolism: Risk includes Venous Thromboembolism (VTE) (such as Deep Vein Thrombosis and Pulmonary Embolism) and Arterial Thromboembolism (ATE) (such as Myocardial Infarction and Stroke).
  • Liver Tumours: The occurrence of certain benign or malignant liver tumours has been reported, classified as very rare.

Time-Related Safety Patterns indicate that bleeding irregularities are most likely to occur during the first few months of use. The risk of serious cardiovascular events is increased for smokers over 35 years old.

Safety is formally restricted for certain individuals. The medicine is contraindicated in the presence or history of VTE/ATE, known or suspected breast cancer or other sex-steroid-influenced malignancies, severe hepatic disease, and undiagnosed abnormal vaginal bleeding.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Melodia (Ethinyl Estradiol and Gestodene) overdose focuses on specific clinical manifestations and mandated emergency actions, as the acute event is not expected to be life-threatening.

Category Officially Documented Statement
Documented Manifestations Acute over-ingestion may present with Nausea, Vomiting, Headache, Breast tenderness, and Withdrawal bleeding (heavy vaginal bleeding) as the primary physical signs.
Severity Classification Overdosage is generally classified in regulatory documents as not likely to cause severe toxicity or result in a life-threatening outcome.
Population Notes The symptom profile, specifically including withdrawal bleeding, is documented in cases of accidental ingestion by prepubertal children.

Required Emergency Actions and Management

Regulators mandate that immediate medical attention must be sought following a known or suspected overdose. The official instruction includes contacting emergency services or the Poison Help hotline. Urgent medical evaluation is required, especially if the over-ingestion is deliberate or if the person exhibits unexpected severe symptoms.

Management is restricted to symptomatic and supportive treatment as the official label confirms no specific antidote is known for this hormonal combination. The protocol requires monitoring of vital signs by a medical provider, which may include blood and urine tests.

Therapeutic Uses of Melodia

What Melodia Treats: Main Uses and Benefits

Melodia, a combined hormonal contraceptive, is commonly used in situations involving certain distressing symptoms across three therapeutic domains. The medication's primary therapeutic domain is commonly used for managing the risk of unintended pregnancy. It is applied across domains where additional symptomatic support is needed, assisting females of reproductive potential, which helps maintain a sense of stability in long-term planning.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms, including severe menstrual pain (primary dysmenorrhea), irregular or heavy menstrual bleeding, and moderate acne vulgaris. This therapy may assist with maintaining functional stability when symptoms become more noticeable.

“The primary therapeutic domain is managing the risk of unintended pregnancy, and the resulting cycle regulation contributes to improved day-to-day comfort.”

Supportive Therapeutic Domains

Melodia is relevant for easing symptoms that become more disruptive during flare-ups, assisting with manifestations of systemic imbalance such as those related to acne. For conditions involving symptoms related to physical discomfort like cramping, the medicine may assist with cycle symptom management.

Quick Fact: Relief for Pain and Irregularity
This therapy assists with maintaining functional stability when symptoms related to cycle disruption or pain interfere with routine activities.

Eligibility and Restrictions for Use

Melodia, a combined oral contraceptive (Ethinyl Estradiol and Gestodene), is primarily intended for use by post-menarcheal females of reproductive age for pregnancy prevention. Official regulatory documents define strict criteria for eligibility, classifying populations as either allowed, restricted, or contraindicated.

Eligibility Status by Population

Population Group Official Regulatory Status
Post-Menarcheal Females (Adults/Adolescents) Allowed (Established use for contraception)
Pre-Menarcheal Children Contraindicated / Not established (Should not be used before the start of menstruation)
Post-Menopausal / Geriatric Females Not Indicated (Use is generally discontinued at menopause)
Pregnant Women Contraindicated (Must be stopped immediately if pregnancy is suspected)
Breastfeeding Women Not Recommended (May affect milk quantity and composition; hormones pass into milk)

Absolute Contraindications

Melodia is absolutely contraindicated and must not be used in individuals with conditions that significantly increase the risk of serious side effects, particularly cardiovascular and thrombotic events. This includes women with a current or history of blood clots (e.g., deep vein thrombosis, pulmonary embolism, stroke, or heart attack) or conditions that predispose to clotting, such as known thrombophilia. Use is also prohibited in females over age 35 who smoke. Other contraindications include severe liver disease or tumors, known or suspected hormone-sensitive cancers (like certain breast cancers), and migraine with focal neurological symptoms (aura).

What should I know about interactions with other medicines?

The interaction profile for Melodia (Ethinyl Estradiol and Gestodene) is strictly governed by regulatory classifications detailing prohibited combinations and pharmacokinetic risks that alter drug exposure.

Regulatorily Prohibited Combinations

Co-administration is contraindicated with certain anti-Hepatitis C Virus (HCV) regimens, including those containing Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, as well as regimens with Glecaprevir/Pibrentasvir or Sofosbuvir/Velpatasvir/Voxilaprevir. This restriction is mandatory due to the officially documented risk of significant liver enzyme (ALT) elevations.

Interactions Altering Hormone Concentration

Interaction Type Interacting Substances (Examples) Official Outcome & Restriction
Enzyme Induction Hepatic enzyme inducers (Rifampin, Phenytoin) and the herbal product St. John’s Wort. Reduces plasma concentration of the hormones, potentially decreasing contraceptive effectiveness. Requires using a back-up non-hormonal method when co-administered.
Enzyme Inhibition Tizanidine, Caffeine (CYP1A2 substrates). Melodia markedly increases plasma concentrations and effects of these medicines due to reduced clearance.

Absorption and Timing Considerations

The drug's effectiveness may be reduced if vomiting or severe diarrhea occurs within four hours of taking the tablet, which is regulated as absorption interference requiring a specific administrative response. Co-administration with Grapefruit or Grapefruit Juice may also alter absorption and change the amount of medicine absorbed.

Mechanism of Action

How Melodia Works: Mechanisms of Action


Receptor-Mediated Signaling Modulation

Melodia engages mechanisms that modulate biological processes by acting as a selective agonist at the Progesterone Receptor (PR), and as an antagonist at both the Mineralocorticoid Receptor (MR) and the Androgen Receptor (AR). This distinct multi-target profile modifies early molecular steps that shape subsequent systemic physiological outcomes.


Pathway Modulation and Systemic Effects

The PR agonist activity influences the hypothalamic-pituitary-ovarian axis, leading to the suppression of pituitary gonadotropin release. This action modulates the activity of mediators within the ovarian feedback loop, resulting in a reduction of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) output.

Simultaneously, antagonism at the MR alters pathway activity associated with the renin-angiotensin-aldosterone system, initiating a sequence that modifies downstream electrolyte and fluid transport processes, resulting in the modification of water and electrolyte excretion/retention. AR antagonism further modifies signaling patterns within androgen-dependent metabolic pathways.

Dosage and Administration Information

Official Administration Guidelines

Melodia is an oral contraceptive intended for oral use only, requiring the daily intake of a fixed-dose tablet. Each active tablet contains the regulated dose of 0.075 mg Gestodene and 0.03 mg Ethinyl Estradiol. The medication is used by adults and teenagers of reproductive potential.


Cyclic Dosing and Timing Protocols

The administration schedule operates on a continuous, cyclic pattern defined by a 28-day regimen. The primary protocol mandates taking one tablet once daily at the same time every day.

The full 28-day cycle consists of:

  • 21 consecutive days of active tablets.
  • A subsequent 7-day hormone-free interval (or 7 inactive tablets) before starting the next pack.

To ensure consistent use, the tablet must be taken at the same time every day and strictly in the sequence directed by the blister pack. Administration can occur without regard to meals (with or without food).

Special Procedural Constraints

Official instructions detail specific protocols for handling any missed active tablets, which is critical for adherence to the intended regimen. Depending on the number of missed tablets and the week in the cycle, the official guidelines may necessitate the temporary use of a non-hormonal barrier method for seven consecutive days to maintain the administration plan as intended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Varenicline


Evidence for use in Smoking Cessation

The use of varenicline was explored in research related to adult smoking cessation. Research examined this in many individuals, including those with no major health issues and certain groups with stable health conditions. Studies monitored continuous abstinence from smoking, measured over specific time intervals.

The majority of evidence comes from controlled studies. Studies reported measurements of continuous abstinence at the measured time points, often up to one year, and described patterns of outcomes in the observed populations. Research highlights changes measured during the study period related to self-reported nicotine craving and withdrawal symptoms.

However, the long-term effects are not fully established beyond one year. Data for certain groups remain insufficient, including adolescents and pregnant individuals, meaning the results apply only to the populations studied.


Evidence for use in Alcohol Consumption Reduction

Varenicline was evaluated in studies exploring outcomes related to the reduction of alcohol consumption in individuals who engage in heavy drinking. These research explored short-term symptom changes, focusing on the number of heavy drinking days per week.

Studies reported that individuals who received the drug was associated with measured changes in the number of heavy drinking days and the total amount of alcohol consumed per week over the study duration. Studies reported measurements of self-reported alcohol craving as well.

The evidence is limited because the number of studies conducted for this purpose was small. Follow-up durations were limited, meaning long-term effects are not fully established past six months.


Research on Post-Cessation Body Weight Measurements

This research is primarily evidence derived from settings with varying symptom burdens within the larger smoking cessation studies. During the short-term treatment period, some trials reported measurements of body weight change, where individuals receiving varenicline were observed to have different measurements of weight gain compared to some control groups. However, research explored whether these measurements of weight change persisted once the treatment was stopped, with varied findings reported.


What Research Still Needs to Address (Uncertainties)

Evidence highlights what is known — and what is still uncertain about varenicline. Follow-up durations were limited for many outcomes. Sample sizes were modest in some specific subgroup analyses, and data for certain groups remain insufficient. The evidence quality varies across studies, and research does not determine whether an individual outside of the studied populations will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Melodia (FAQ)


Q: How does Melodia compare to older medicines used for the same condition?

Official documentation classifies the progestin component, Gestodene, as a third-generation progestin. Studies have examined this profile, indicating it was associated with different measured outcomes for side effects such as weight gain and breast tenderness, compared to some earlier formulations.


Q: Is it safe to take herbal supplements or vitamins with Melodia?

According to the official product information, certain herbal products like St. John’s Wort can alter the plasma concentration of the active ingredients, which is described as potentially decreasing contraceptive effectiveness. Specific warnings for general vitamins are typically not provided in the product label.


Q: Can Melodia be used by people who have an existing heart condition?

Regulatory documents state that Melodia is formally contraindicated for individuals who have a history of, or are currently experiencing, blood clots in the veins or arteries, such as deep vein thrombosis, stroke, or heart attack. The determination of suitability for other pre-existing heart conditions is guided by formal medical eligibility criteria.


Q: What are the concerns about using Melodia during pregnancy or while breastfeeding?

Official documentation states this medication is formally contraindicated for use during pregnancy, as it is a contraceptive. Official documents state that use during lactation (breastfeeding) is generally not recommended due to the potential for systemic exposure in the infant.


Q: Will taking Melodia cause or worsen anxiety or sleeping problems?

The safety profile lists mood changes, including depression, as a common adverse reaction. Official documentation does not typically list anxiety or specific sleeping problems as common adverse reactions. The full list of potential effects is available in the official product label.


Q: Can Melodia be taken by someone with a history of diabetes or high blood pressure?

The use of combined hormonal contraceptives for individuals with existing conditions like diabetes or high blood pressure (hypertension) is formally assessed using medical eligibility criteria defined by health organizations. Official safety data also lists high blood pressure as an uncommon adverse reaction associated with the drug.


Q: Is Melodia a short-term treatment or something I will need to take long-term?

Melodia is designed for continuous, cyclic use for the primary purpose of contraception. Official documents support its use over extended periods of time, and ongoing medical evaluation is part of the established treatment protocol.


Q: How long does it usually take to feel the effects of Melodia?

The onset of contraceptive protection is described in regulatory documents as typically beginning after the first seven consecutive days of active tablet use, assuming the administration instructions are followed as directed.


Q: Are the side effects of Melodia permanent, or do they eventually go away?

The official safety profile notes that certain adverse reactions, such as bleeding irregularities, are most common during the first few months of use. These reactions are often reported to diminish during continued use. Official documents state that persistent adverse reactions require assessment.


Q: Will taking Melodia affect my ability to drive or perform other tasks requiring focus?

Official documentation indicates that this medication has not been reported to be associated with causing drowsiness or impairing driving ability. Its use is therefore considered compatible with driving and operating machinery.


Q: How long after my last dose of Melodia is it safe to consume alcohol?

Official safety information indicates that limited data are available regarding the interaction of this medication with alcohol. For this reason, the official product label generally recommends exercising caution.


Q: Where can I find the official, regulatory-approved patient information for Melodia?

Official prescribing information, such as the DailyMed (FDA) or SmPC (EMA) document, can be obtained from the relevant government health authority’s public website. These documents contain the full, regulatorily approved details about the product.


Q: What does the latest research evidence indicate about the long-term use of Melodia?

Research has examined the use of this combined hormone therapy over extended cycles, which is beyond the standard 28-day regimen. Evidence indicates the maintenance of contraceptive efficacy and a safety profile comparable to the standard regimen.


Q: Is it necessary to have routine blood tests while taking Melodia?

Official regulatory bodies recommend measurements of blood pressure and body weight prior to initiation. The requirement for any additional routine laboratory tests is addressed within the established medical guidelines.


Q: What should I look out for if I suspect an allergic reaction to Melodia?

Official instructions detail that signs of a severe allergic reaction, such as swelling of the face, tongue, or throat, or a severe generalized rash, require immediate clinical assessment.


Q: Is it normal to feel tired or have low energy when first starting Melodia?

Clinical studies have measured patient-reported symptoms, and some individuals taking this drug combination reported tiredness during the treatment period. This symptom is documented in the context of clinical observations.


Q: Is there any information on how Melodia affects fertility?

Official documents describing the use of combined hormonal contraceptives indicate that the return of normal ovarian function and the ability to conceive is expected after the medication is discontinued.


Q: What is the shelf life of Melodia before it expires?

The specific shelf life (expiry date) for the product is printed directly on the original package. Adherence to this date is necessary to maintain the integrity and intended effectiveness of the medication.


Q: Will I experience a withdrawal effect if I stop taking Melodia?

The scheduled hormone-free interval in the 28-day cycle is intended to result in a withdrawal bleed (a scheduled event). Official information also states that normal ovarian function returns after stopping the drug.


Q: How quickly does Melodia leave the system after the last dose is taken?

Pharmacokinetics data, available in the official product label, detail the half-life of each active component, which is the measure used to describe its rate of clearance from the body.

How should Melodia be stored and disposed of?

How to Store and Dispose of Melodia?

The storage and handling of Melodia (Ethinyl Estradiol/Gestodene) must follow specific regulatory requirements to maintain product stability and ensure safety.


Storage Requirements

The tablets must be stored at a temperature not above 30 C (86 F). The product must be kept in its original package (blister pack) to protect it from both light and moisture. Regulatory labeling specifies do not refrigerate or freeze the medicine. Consistent with all oral medications, Melodia must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Melodia tablets must be disposed of according to local requirements. The official instructions explicitly state do not throw away any medicines via wastewater or household rubbish. The proper procedure often involves returning the unused medicine to a pharmacist for appropriate pharmaceutical waste handling, which protects the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melodia found in:

A-Z Index: